Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistanceMeghna Das Thakur, Darrin D. Stuart, Fernando Salangsang et al.|Nature|2013Cited by 735
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant XenograftsLeonard Buckbinder, Darrin D. Stuart|Cancer Discovery|2023Cited by 67
Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic MelanomaTeresa E. Williams, Daniel Poon, Maureen McKenna et al.|ACS Medicinal Chemistry Letters|2015Cited by 54
CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutationsPayman Amiri, Renhow Paul, Mina Aikawa et al.|Cancer Research|2006Cited by 25
Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase InhibitorsSharadha Subramanian, Savithri Ramurthy, Abran Costales et al.|ACS Medicinal Chemistry Letters|2014Cited by 13